Clairity – developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram For the first time, clinicians ...
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results